Yes, there are efficacy/variant differences between the vaccines and at some point, there will be sorting through all that, and boosters. But right now, billions remain unvaccinated because there isn't enough of *any* vaccine available to them. That just has to be the priority.
-
-
Show this threadThanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
30,000 of us participated in US trial, now what do we do if Novavax not in US for booster? Would not participate in another trial if I am handicapped in doing so. Also what about misguided mRNA hesitant people in US who would take a traditional vax, could see 5%+ lift in vaxed
-
Also, who wants to take mRNA, or even adeno (!!!) as 3rd jab booster?
$NVAX - Show replies
New conversation -
-
-
I think it is a good idea to have some diversity in vaccine types, especially if they end up using resources that do not compete with other vaccines already in production. Plus, the virus mutates and it is possible that a future mutation may render some vaccines obsolete
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
I wonder if some Americans who don't trust mRNA vaccine will be willing to get Novavax vaccines.
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
and more flexible storage requirements could make a huge difference in terms of reaching more people in more places.
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.